Having trouble accessing articles? Reset your cache.

Trastuzumab-DM1 regulatory update

FDA refused to file a BLA from Genentech Inc. for trastuzumab-DM1 (T-DM1) for third-line advanced HER2-positive breast cancer. The application, which was submitted last month, had requested accelerated

Read the full 286 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE